Dario Trapani, Medical Oncologist at European Institute of Oncology (IEO), Researcher at Department of Oncology and Hemato-Oncology at University of Milan, shared ESMO’s post, adding:
“Immunotherapy, for all its success, may be like the so-called unfinished works of the Italian sculptor Michelangelo, whose impact on humanity lies not only in what has been revealed, but in what remains to be refined. Asking ourselves, as medical oncologists, whether less might sometimes be enough does not mean downgrading immunotherapy’s achievements; rather it reflects a continuous commitment to taking them seriously enough to interrogate its foundations to further advance the field in a sustainable and more equal way.
Find here for more on class effect, near equivalence, IO dosing and dose finding paradigms with an eye to implementation and action!”
Quoting ESMO’s post:
“Immunotherapy has transformed Cancer Care—but its success comes with an ethical paradox: life-saving treatments remain inaccessible for most patients worldwide. With WHO listing immunotherapy as essential medicine, dosing is no longer a technical detail—it’s an ethical and clinical issue. Evidence suggests that lower doses may achieve comparable benefit, challenging the assumption that maximal dosing equals maximal efficacy.
Read more in the ESMO Daily Reporter.”
More posts featuring Dario Trapani.